| Patients |
| Number (N = 44) | Percentage (%) | Follow-up Duration (weeks) |
| Age (years) | <55 | 1 | 2.27% | 112.714286 |
| 55 - 59 | 9 | 20.45% | 1000.28571 | |
| 60 - 64 | 5 | 11.36% | 759.857143 | |
| 65 - 69 | 5 | 11.36% | 519.285714 | |
| 70 - 74 | 9 | 20.45% | 1222 | |
| 75 - 79 | 8 | 18.18% | 803.428571 | |
| 80 - 84 | 3 | 6.82% | 240.142857 | |
| >85 | 4 | 9.09% | 302.714286 | |
| PSA (ng/ml) | <4 | 0 | 0.00% | 0 |
| 4 - 19.9 | 0 | 0.00% | 0 | |
| 20 - 99.9 | 5 | 11.36% | 651.142857 | |
| 100 - 199.9 | 7 | 15.91% | 947.571429 | |
| 200 - 499.9 | 19 | 43.18% | 2245 | |
| 500 - 999.9 | 6 | 13.64% | 602.714286 | |
| >1000 | 7 | 15.91% | 514 | |
| Gleason Score | 6 | 7 | 15.91% | 845.6 |
| 7 (3 + 4) | 12 | 27.27% | 1186.9 | |
| 7 (4 + 3) | 4 | 9.09% | 383.7 | |
| 8 | 9 | 20.45% | 1095.6 | |
| 9 | 10 | 22.73% | 1121.1 | |
| 10 | 2 | 4.55% | 327.6 | |
| Metastasis | Lymph nodes | 40 | 90.91% |
|
| Bone | 26 | 59.09% |
| |
| Lymph node and bone | 22 | 50.00% |
| |
| seminal vesicles | 1 | 2.27% |
| |
| Liver | 3 | 6.82% |
| |
| Lungs | 2 | 4.55% |
| |
| liver and lungs | 2 | 4.55% |
| |
| Creatinine (mg/l) | ≤13 | 22 | 50.00% | 2572 |
| >13 | 22 | 50.00% | 2388.42857 | |
| Hemoglobin (g/dl) | <5 | 0 | 0.00% | 0 |
| 5 - 10 | 26 | 59.09% | 2954.57143 | |
| >10 | 18 | 40.91% | 2005.85714 | |
| Primary Treatment | Pulpectomy | 31 | 70.45% | 3168.0 |
| LHRH Analogues | 13 | 29.55% | 1792.4 | |
| Bisphosphonates | 25 | 56.82% | 2822.6 | |
| Abiraterone | 3 | 6.82% | 470.1 | |
| Enzalutamide | 2 | 4.55% | 101.1 | |
| Docetaxel | 12 | 27.27% | 1663.7 |